{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:26:09Z","timestamp":1786652769444,"version":"build-2736575974"},"reference-count":12,"publisher":"Ubiquity Press, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gh"],"abstract":"<jats:p>Background: A novel low-dose triple single-pill combination of antihypertensive drugs (GMRx2) has demonstrated superior blood pressure (BP)-lowering efficacy compared to placebo and dual combinations in short-term randomized double-blind trials.\nObjectives: To evaluate the long-term BP-lowering efficacy and safety of GMRx2-based treatment when used in normal clinical care.\nMethods: After completing a four-week double-blind randomised phase, participants from Sri Lanka and Nigeria were enrolled into an open-label extension phase (OLE) with follow-up to one year. The OLE involved treatment and uptitration with GMRx2, of \u00bc, \u00bd and standard doses of telmisartan\/amlodipine\/indapamide (i.e., 10\/1.25\/0.625 mg, 20\/2.5\/1.25 mg and 40\/5\/2.5 mg), and add-on antihypertensive drugs if needed to target a home BP goal of &lt;130\/80 mm Hg. Home BP monitoring was continued throughout the follow-up and six follow-up clinic visits were conducted. The primary outcome was percentage of participants with home BP control (&lt;130\/80 mmHg) at week 52.\nResults: From 21 August 2023 to 20 August 2024, 50 participants participated in the OLE, of whom 48 (96%) completed it. The mean age of participants was 49 years and 60% were female. Home and clinic mean BP at enrolment into OLE were 126\/79 mmHg and 131\/83 mmHg, respectively. At one year, home BP control (&lt;130\/80 mmHg) was 60% and clinic BP control (&lt;140\/90 mmHg) was 88%. Home mean BP was reduced to 121\/78 mmHg after 4 weeks into the OLE and was 120\/78 mmHg at one year. For clinic BP, the corresponding values were 126\/79 mmHg and 122\/77 mmHg. None of the participants discontinued trial treatment due to an adverse event.\nConclusions: In a population with mild-to-moderate hypertension, long-term therapy with GMRx2-based treatment achieved high levels of BP control and was well tolerated.\nTrial registration: NCT04518306.<\/jats:p>","DOI":"10.5334\/gh.1481","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:20:36Z","timestamp":1761909636000},"page":"102","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination for the Treatment of Hypertension"],"prefix":"10.5334","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-7936","authenticated-orcid":false,"given":"Abdul","family":"Salam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-6861","authenticated-orcid":false,"given":"H. Asita","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-1988","authenticated-orcid":false,"given":"Dike","family":"Ojji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Galappatthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lakshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kumanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mayurathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rahuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ranasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rasnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Uluwattage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thambyaiah","family":"Kandeepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Umar","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-2972","authenticated-orcid":false,"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-3567","authenticated-orcid":false,"given":"Gian Luca","family":"Di Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4472-4468","authenticated-orcid":false,"given":"Diederick","family":"Grobbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-5018","authenticated-orcid":false,"given":"Krzysztof","family":"Narkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-2599","authenticated-orcid":false,"given":"Suzanne","family":"Oparil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-997X","authenticated-orcid":false,"given":"Neil R.","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":false,"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-4937","authenticated-orcid":false,"given":"Aletta E.","family":"Schutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-6407","authenticated-orcid":false,"given":"Wilko","family":"Spiering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8094-1841","authenticated-orcid":false,"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson T.","family":"Wright, Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-9007","authenticated-orcid":false,"given":"Chris","family":"Gianacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathangi","family":"Shanthakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-1896","authenticated-orcid":false,"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3285","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"key20251031112032_B1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: A randomized clinical trial","volume":"320","year":"2018","journal-title":"JAMA"},{"key":"key20251031112032_B2","first-page":"19","article-title":"Rationale for a new low-dose triple single pill combination for the treatment of hypertension","year":"2024","journal-title":"Glob Heart"},{"key":"key20251031112032_B3","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.jacc.2024.08.025","article-title":"Efficacy and safety of a novel low-dose triple single-pill combination compared with placebo for initial treatment of hypertension","volume":"84","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"key20251031112032_B4","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(24)01744-6","article-title":"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial","volume":"404","year":"2024","journal-title":"The Lancet"},{"key":"key20251031112032_B5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"The Lancet"},{"key":"key20251031112032_B6","first-page":"1771","article-title":"How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data","volume":"97","year":"2011","journal-title":"Heart Br Card Soc"},{"key":"key20251031112032_B7","first-page":"e35","article-title":"Measurement of blood pressure in humans: A scientific statement from the American Heart Association","volume":"73","year":"2019","journal-title":"Hypertens Dallas Tex 1979"},{"key":"key20251031112032_B8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12325-014-0117-9","article-title":"Open-label study assessing the long-term efficacy and safety of triple olmesartan\/amlodipine\/hydrochlorothiazide combination therapy for hypertension","volume":"31","year":"2014","journal-title":"Adv Ther"},{"key":"key20251031112032_B9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s12325-017-0572-1","article-title":"The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: The results of the PETRA study","volume":"34","year":"2017","journal-title":"Adv Ther"},{"key":"key20251031112032_B10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40261-014-0223-0","article-title":"Triple combination therapy in hypertension: The antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR","volume":"34","year":"2014","journal-title":"Clin Drug Investig"},{"key":"key20251031112032_B11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40256-014-0067-2","article-title":"Antihypertensive efficacy of triple combination perindopril\/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients)","volume":"14","year":"2014","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"key20251031112032_B12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40119-024-00358-5","article-title":"Single-pill, triple antihypertensive therapy in rural sub-Saharan Africa: Preliminary experience","volume":"13","year":"2024","journal-title":"Cardiol Ther"}],"container-title":["Global Heart"],"original-title":[],"link":[{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1481\/2155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1481\/2156","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1481\/2157","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1481\/2155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:31:57Z","timestamp":1761910317000},"score":1,"resource":{"primary":{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/view\/1481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.5334\/gh.1481","relation":{},"ISSN":["2211-8179","2211-8160"],"issn-type":[{"value":"2211-8179","type":"electronic"},{"value":"2211-8160","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}